Immunotherapy: Empowering Nature’s Anti-Tumor Artillery - Part I


Posted by Liana G on Dec 6, 2017 6:15:00 AM

Immunotherapy as an anti-neoplastic strategy has gradually claimed the spotlight over the past several years. In fact, some now consider it as one of the pillars of cancer therapy along with chemotherapy, radiation, surgery, and targeted therapy. Scientists and clinicians alike are cautiously optimistic, and point to response rates never seen before. 

And, why not take advantage of our own immune system and the best of its weaponry, the T cells, to fight cancer?

READ MORE >

Topics: Cancer Immunology, Journal Club

Webinar | Key signaling pathways in cancer: Emerging trends in immunometabolism


Posted by Carolyn P on Mar 22, 2017 7:00:00 AM

 

Immune cells divide rapidly when mounting an immune response against a pathogen, for example, or when initiating a wound-healing response. To accommodate the increased energy requirements to mount the immune response, these cells may employ metabolic pathways similar to those engaged by cancer cells—pathways such as aerobic glycolysis. This correlation presents the intriguing possibility that understanding immune cell metabolism will provide new and actionable insights into the behavior of tumor cells. In this webinar, our expert speakers will explore how this phenomenon is being studied and describe how it could enable the development of new strategies in the fight against cancer. 

READ MORE >

Topics: Cancer Immunology, Cancer Research, Webinars

Webinar | Deciphering Cancer: Genomic Instability in Cancer


Posted by Carolyn P on Nov 30, 2016 3:00:00 AM

 

While it is well established that DNA damage can increase the risk of cancer, changes to the epigenome or the chromatin architecture are equally important. DNA damage triggers a redistribution of DNA-binding proteins around the site of damage, resulting in localized and temporary alteration of chromatin structure. However, repeated cycles of DNA damage and repair may lead to permanent changes in the epigenome, thereby promoting the onset of diseases such as cancer. This webinar will examine how we may be able to develop effective new therapeutic options for cancer treatment by targeting proteins responsible for chromatin modifications.

READ MORE >

Topics: Cancer Immunology, Cancer Research, Webinars

Webinar | Targeting Cancer Pathways: Understanding Immune Checkpoints


Posted by Carolyn P on Aug 17, 2016 3:00:00 AM

 
In this webinar, the speakers will explore how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment. In addition, they will:
READ MORE >

Topics: Cancer Immunology, Cancer Research, Webinars

Webinar - Multiplex Immunohistochemistry (IHC)


Posted by Liana G on Jun 8, 2016 3:00:00 AM

Analysis of Immune Checkpoint Control Protein Co-expression in Breast and Ovarian Cancer Using Novel Rabbit Monoclonal Antibodies and Multiplex IHC

With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes. IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information.

Watch the video below.

 

READ MORE >

Topics: Protocols, IHC, Cancer Immunology, Cancer Research, mIHC

Webinar | Targeting Cancer Pathways: Understanding Immune Checkpoints


Posted by Carolyn P on Feb 3, 2016 3:00:00 AM

In this webinar, the speakers will explore how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment. In addition, they will:
READ MORE >

Topics: Cancer Immunology, Cancer Research

Immunotherapy: Empowering Nature’s Anti-Tumor Artillery - Part I


Posted by Liana G on Jan 27, 2016 3:00:00 AM

If you happened to attend AACR, AAI, or ASCO this year you’d agree that immune cell-based cancer therapies have caused quite the stir. Immunotherapy as an anti-neoplastic strategy has gradually claimed the spotlight over the past several years. In fact, some now consider it as one of the pillars of cancer therapy along with chemotherapy, radiation, surgery, and targeted therapy. Scientists and clinicians alike are cautiously optimistic, and point to response rates never seen before. 

And, why not take advantage of our own immune system and the best of its weaponry, the T cells, to fight cancer?

READ MORE >

Topics: Cancer Immunology

Webinar - Multiplex Immunohistochemistry (IHC)


Posted by Liana G on Jan 13, 2016 3:00:00 AM

Analysis of Immune Checkpoint Control Protein Co-expression in Breast and Ovarian Cancer Using Novel Rabbit Monoclonal Antibodies and Multiplex IHC

With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes. IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information.

Watch the video below.

 

READ MORE >

Topics: Protocols, IHC, Cancer Immunology, Cancer Research, mIHC

POSTER | Tumor Immunology: Examining the Microenvironment


Posted by Liana G on Oct 21, 2015 5:30:00 AM

The immune system is tasked with distinguishing ‘self’ from ‘non-self’. Tumors can, quite often, be highly immunogenic as a result of their mutational burden that can make them appear less like ‘self’.

READ MORE >

Topics: Cancer Immunology, Just for fun

Immunotherapy: Empowering Nature’s Anti-tumor Artillery - Part II


Posted by Liana G on Sep 9, 2015 8:00:00 AM

At your last visit we talked about the rapidly rising popularity of cancer immunotherapy and how it relies on capitalizing on our own immune system to eradicate malignant growth. 

We discussed the benefits of immune checkpoint blockade involving neutralizing monoclonal antibodies as a successful strategy in unmasking cancer cells, thus making them vulnerable to immune attack. So successful, in fact, that cancer immunotherapy based on this strategy was named ‘breakthrough of the year’ in 2013.

Having said that, not all patients respond to checkpoint blockade. Hence, there is much room for improvement and a pressing need for alternative approaches and better characterized biomarkers that can help stratify patients and make more accurate predictions on the prognostic outcome of a given treatment.

So, what are some of the advancements made in developing additional immunotherapeutic strategies to tackle cancer?

READ MORE >

Topics: Cancer Immunology